Raymond James Boosts UnitedHealth (UNH) Rating Before Q1 Results

Raymond James Boosts UnitedHealth (UNH) Rating Before Q1 Results

UnitedHealth Group Inc. (UNH) shares surged 1.2% on April 2, 2026, following a rating upgrade by Raymond James. The analyst firm upgraded the stock from "Market Perform" to "Outperform," setting a target price of $330. This action comes as the company prepares to release its first-quarter earnings on April 21, 2026. Analysts anticipate earnings per share (EPS) of $6.69, reflecting an 8% year-over-year decline, alongside $109.58 billion in revenue.

UnitedHealth has faced a challenging start to 2026, with its stock dropping approximately 17% year-to-date. The decline has been driven by disappointing forward guidance and persistent issues within its Medicare Advantage segment. This selloff has even pushed the stock below the entry point established by Berkshire Hathaway, sparking discussions about potential value at current levels.

Despite the challenges, Raymond James analyst John Ransom believes the market is underestimating UnitedHealth's earnings potential. He points to operational efficiency gains as a key factor, emphasizing that administrative expense optimization could significantly impact the company's bottom line. Ransom's analysis suggests that each 100-basis-point reduction in general and administrative costs could contribute positively to earnings.

The upgrade by Raymond James has prompted a noticeable rally in UnitedHealth's stock price. On April 2, shares climbed approximately 1.2% in response to the analyst action, reaching $279.04 before closing at $277.30.

Derivatives markets also reflect heightened anticipation for UnitedHealth's earnings announcement. Options activity indicates traders expect around 9% volatility in either direction once the results are released. This suggests that the market is bracing for significant swings in the stock price following the earnings report.

As UnitedHealth prepares to unveil its first-quarter financial performance, investors and analysts are closely watching the company's ability to navigate the challenges it has faced. The recent rating upgrade by Raymond James provides a glimmer of optimism, but the upcoming earnings report will be crucial in determining whether the stock can recover from its recent downturn.

In the lead-up to the earnings announcement, the market will likely scrutinize UnitedHealth's revenue growth, EPS performance, and any updates on its strategic initiatives. Investors will also be keen to see if the company can deliver on its operational efficiency goals, which could help mitigate some of the pressures weighing on its stock price.

In conclusion, the recent rating upgrade by Raymond James has provided a boost to UnitedHealth's stock, but the company still faces significant challenges ahead. The upcoming first-quarter earnings report will be pivotal in determining the stock's trajectory and whether it can recover from its recent decline. With analysts anticipating a modest EPS figure and heightened volatility in derivatives markets, the focus will be on whether UnitedHealth can deliver strong operational performance and meet investor expectations.